Drug Profile

BCG 009

Alternative Names: BCG-009; NTB 003

Latest Information Update: 16 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Beijing Biocytogen
Class Eye disorder therapies; Monoclonal antibodies
Mechanism of Action Insulin-like growth factor I inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Graves ophthalmopathy

Most Recent Events

01 Mar 2026 Nanjing Chia-tai Tianqing Pharmaceutical plans a phase I trial for Graves ophthalmopathy (SC) in March 2026 (NCT07462130)
04 Jun 2025 The National Medical Products Administration (NMPA) approves IND application for BCG 009 in Graves ophthalmology
07 May 2025 BCG 009 is available for licensing as of 07 May 2025. BD-Licensing@biocytogen.com (Beijing Biocytogen Communication, May 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com